We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 16.75 | 950,002 | 07:33:54 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 16.50 | 17.00 | 16.75 | 16.75 | 16.75 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 1.21M | -2.88M | -0.0127 | -13.19 | 37.87M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:13:27 | O | 500,000 | 16.95 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 30/6/2025 | 07:00 | UK RNS | SkinBioTherapeutics PLC Croda Commercial Launch Progressing as Expected |
| 27/6/2025 | 07:00 | UK RNS | SkinBioTherapeutics PLC Notice of IMC Shareholder Presentation |
| 25/6/2025 | 11:28 | UK RNS | SkinBioTherapeutics PLC Holding(s) in Company |
| 20/6/2025 | 13:18 | ALNC |  IN BRIEF: SkinBioTherapeutics raises GBP4 million for Superdrug deal |
| 20/6/2025 | 07:00 | UK RNS | SkinBioTherapeutics PLC Result of WRAP Retail Offer |
| 16/6/2025 | 21:53 | ALNC | TRADING UPDATES: SkinBioTherapeutics hails "milestone" Superdrug deal |
| 16/6/2025 | 14:02 | UK RNS | SkinBioTherapeutics PLC WRAP Retail Offer |
| 16/6/2025 | 07:00 | UK RNS | SkinBioTherapeutics PLC Superdrug agreement, Placing & Retail Offer |
| 22/5/2025 | 12:44 | UK RNS | SkinBioTherapeutics PLC Correction: Change of Adviser |
| 22/5/2025 | 07:00 | UK RNS | SkinBioTherapeutics PLC Change of advisor |
Skinbiotherapeutics (SBTX) Share Charts1 Year Skinbiotherapeutics Chart |
|
1 Month Skinbiotherapeutics Chart |
Intraday Skinbiotherapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/7/2025 | 23:17 | SkinBioTherapeutics PLC | 9,146 |
| 09/7/2025 | 18:51 | SBTX ust mucking around - please ignore | 2,102 |
| 09/7/2025 | 13:34 | THE TROLL FREE 2025. - 2030 SBTX POTENTIAL 100 BAGGER RESEARCH THREAD. | 534 |
| 09/7/2025 | 08:33 | SkinBioTherapeutics PLC - Multi $bn skin health opportunities. | 30,651 |
| 22/4/2025 | 12:06 | The new Matrixyl set to revolutionise skin care | 121 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-07-09 15:52:54 | 16.95 | 500,000 | 84,750.00 | O |
| 2025-07-09 15:13:28 | 16.94 | 1,180 | 199.89 | O |
| 2025-07-09 15:06:27 | 16.95 | 35,314 | 5,985.37 | O |
| 2025-07-09 13:56:57 | 16.80 | 20,000 | 3,360.00 | O |
| 2025-07-09 13:56:52 | 16.80 | 30,000 | 5,040.00 | O |
| Top Posts |
|---|
Posted at 09/7/2025 09:20 by Skinbiotherapeutics Daily Update Skinbiotherapeutics Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker SBTX. The last closing price for Skinbiotherapeutics was 16.75p.Skinbiotherapeutics currently has 226,086,285 shares in issue. The market capitalisation of Skinbiotherapeutics is £37,869,453. Skinbiotherapeutics has a price to earnings ratio (PE ratio) of -13.19. This morning SBTX shares opened at 16.75p |
Posted at 09/7/2025 07:54 by sunshine today when the SBTX share price was 16.75p. Good morning.It appears the new house broker has published a share price target of 29p in their initiation coverage of SBTX My takeaway : Very pleased : it is a low ball number ( but still with a good 60% upside ). I have set myself a target of Ten broker upgrades within the next 4 years as Zenakine sales grow rapidly and Ashman drives the other 4 pillars forward, at pace. I have penciled two of those upgrades, within 6 months of today. |
Posted at 06/7/2025 10:45 by sunshine today when the SBTX share price was 16.625p. Last week Mr Ashman updated investors .His words. Matrixyl and Retinol currently produce hundreds of millions of sales for Croda. Zenakine is the replacement bio ingredient going forward. Assume the rate of royalty payment is 12.5% to SBTX Assume over time £200M of annual sales of Zenakine ( exc market grab ,from others ). £25M a year to SBTX is a number flashed around by Mr Ashman for the last few years as potential income from Croda to SBTX. That number looks totally realistic to me. Assuming continued rapid growth, profits from other SBTX pillars, and a very low tax charge . Where might we be on valuation terms if the above is correct : I would stab at £750M towards £1BN Timeline 4 - 5 years, could be quicker. £43M Market cap today ; Investors this Sunday, clearly have a very real chance, to do exceptionally well. These numbers may be on the very low side, if the cosmetic industry picks Zenakine as the Gold standard , ( like Matrixyl has been for 20 plus years ), it gains first mover advantage , and rapid adoption. My personal take : after wholesale change over to bio, Zenakine will remain market leader. The opportunity for Croda to gain market share from others over the next 24 months is staggering. The potential market size is ITRO £800M : (Retinol replacement and Zenakine sleep properties ). Reading the last Croda update we see the game plan is to increase sales and margins within beauty actives. Croda itself is under pressure to produce a rapid improvement in operating margin. All this bodes very well for SBTX shareholders. 28% compound has done me very well over the last 20 years or a 60p SBTX share price, in 5 years time. My sums above would produce ITRO £3.20 SBTX share price in five years time . !! Hence : heaps to go for, plus, a huge safety net if performance fails to hit my expectations. Ashman says Zenakine now requires zero time , effort , or cost. He can now get on with producing yet more growth within the five pillars of SBTX. |
Posted at 05/7/2025 08:26 by socionomics when the SBTX share price was 16.625p. We know how big this is going to be. :)In other news: I exported the last few days’ worth of trades into Excel and split them into thirds based on price transacted. I did this for each day to factor-in share price movements. Top third of transaction prices (almost certainly buys) Middle third (mixed) Bottom third (almost certainly sales) The results were conclusive. Those with deep pockets are buying. DYOR |
Posted at 01/7/2025 08:00 by netcurtains when the SBTX share price was 16.50p. Dud: I have no idea who he is and I know my IQ is pretty low (Seemy autobiography - it explains it all: ====== The NDA or AIM rules have to break. This means if CRODA want to keep Zenakine sales secret they will have to either offer X amount to SBTX to buy the Zenakine part of the business or buy SBTX in total, or SBTX goes private (management buyout). Something has to blow soon..... |
Posted at 30/6/2025 07:12 by sunshine today when the SBTX share price was 16.80p. Good MorningCommercial Launch Progressing as Expected 30 June 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, reports that following the successful global launch of ZenakineTM by Croda Beauty in April 2025, the commercialisation of the product is progressing as expected by management. According to the Croda Beauty website, Zenakine™ is being described as: "…a cutting-edge neuroactive ingredient designed to counteract the effects of stress on the skin and improve overall wellbeing. It works in sync with the skin's natural biological rhythms, enhancing melatonin production to help improve sleep quality, elevating positive emotions and stimulating skin regeneration. It is the first ingredient with clinical instrumental measures on sleep quality and duration benefits." SkinBioTherapeutics has had a long standing commercial and manufacturing agreement with Croda plc since 2019. As a result of the competitiveness of the global cosmetic industry, SkinBioTherapeutics is under a strict confidentiality agreement that prevents it from divulging information on sales or providing market forecasts. //////////////////// Why I like the above RNS. 1/ It informs SBTX all is on track as expected . 2/ It is designed to increase and protect CRODA’S profits from Zenakine, this does exactly the same for SBTX shareholders as we get a 10% plus cut of Zenakine sales. 3/ The NDA also gives those when have bought Zenakine the chance to have meaningful marketing for new product's 4/ The SBTX house broker CAN make forecasts and judgements of sales of Zenakine. 5/ Zenakine sales WILL show up in the SBTX accounts twice a year. |
Posted at 29/6/2025 21:20 by the gerbilator when the SBTX share price was 16.80p. Market Flash: OPTI & SBTX's Synchronized Spike Signals Global Trouble Ahead?Did these two stocks just telegraph the end-of-Q2 chaos we're all dreading? In what can only be described as eerily coordinated market theatre, OPTI and SBTX both delivered spectacular spike-and-crash performances recently, complete with desperate cash raises that have investors wondering if someone got an advance copy of the Q2 finale script. The timing is too perfect to ignore. As we barrel toward quarter-end with global equity markets flashing their first serious warning signals in years, these two companies executed near-identical "emergency funding" manoeuvres that look suspiciously like advance preparation for stormy weather ahead. Both stocks surged on minimal news, then promptly cratered as dilutive offerings hit the tape faster than you could say "liquidity crisis." The playbook was textbook desperation: pump the price, dump the shares, grab the cash, and hope investors don't notice the house is on fire. The bigger question looming over trading floors: Are we witnessing isolated incidents of poor corporate timing, or did OPTI and SBTX just provide a preview of coming attractions for the broader market? With institutional money managers already positioning for volatility and retail investors still blissfully unaware of the gathering storm clouds, the synchronized nature of these moves feels less like coincidence and more like canaries in a very expensive coal mine. The race is now on: Can company backers execute their rapid-fire exit strategies before stock certificates become kindling for the bonfire season? At this point, forget the VIX - OPTI and SBTX might just be the most reliable weathervanes we have for what's coming next. Identical rapid spikes will confirm our thesis-the globe is about to enter a full downturn. Stay tuned. This story is just getting started. |
Posted at 23/6/2025 13:55 by the gerbilator In the interim, im afraid we all have to suffer and defame, all because of sbtx share price haha |
Posted at 23/6/2025 13:37 by the gerbilator Historic reality - inception to todayRed prices - these are the profit centre means on share price from above and below Green prices - their historic max reality paid prices for future profit centre operations. That is fact - inception to today numbers What price was cash raise? Most likely 11.55 net if you ask me lol Ignore volume totals as they are anchor points, not period totals, obviously |
Posted at 12/6/2025 10:38 by netcurtains CAGR stands for Compound Annual Growth Rate:Is 14.5% CAGR good? Yes, a 14.5% CAGR per year is considered excellent in most investment scenarios. Here's why: Stock Market Benchmark: The long-term average return of the S&P 500 is around 8–10% annually. Doubling Time: At 14.5% CAGR, an investment doubles approximately every 5 years. Comparison: Beating inflation (~2–3%) and fixed-income returns (typically 3–5%) by a wide margin. that is for the BIG PLAYERS but for a small company like SBTX it could blow the roof off the share price... |
Posted at 11/6/2025 14:18 by netcurtains I gave chatGPT loads of variables,including SBTX falling share price, CRODA rising, insider OPTI selling etc etc... And to come up with some rough statistical odds of Zenakine making SBTX significant money.... (I guess anything over £10M sales giving us a £1M profit) 🎲 ROUGH GUESS: Odds of £50M+/yr Sales Factoring in science potential, market trends, and investor signals: Outcome Chance Blockbuster success (£50M+/yr sales) ~20–25% Moderate success (£10M–50M/yr) ~40–45% Low adoption/minimal revenue (< £10M) ~30–40% I then said CRODA made SBTX sign an NDA and OPTI although a very large shareholder is no longer involved in the day to day running of the company.. This changed the odds significantly Blockbuster success (£50M+/yr sales) 25–30% ✅ (slightly up) Moderate success (£10M–50M/yr) ~40% Low adoption/minimal revenue (< £10M) ~30–35% So bottom line (from known facts on the internet) 25% to 30% chance of making wads of cash! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
